Osmolytes and ion transport modulators: New strategies for airway surface rehydration

Current Opinion in Pharmacology

Volumn 10, Issue 3, 2010, Pages 294-299

  Goralski, Jennifer L ^a   Boucher, Richard C ^b   Button, Brian ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AQUAPORIN 3; AQUAPORIN 4; AQUAPORIN 5; CAMOSTAT; DENUFOSOL; DEOXYRIBONUCLEASE; EPITHELIAL SODIUM CHANNEL; GS 9411; INO 4995; MANNITOL; OSMOTIC AGENT; P 552 02; PLACEBO; PURINERGIC P2Y2 RECEPTOR; QAU 145; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHLORIDE; UNCLASSIFIED DRUG; OSMOTIC DIURETIC AGENT;

BRONCHOSPASM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; MONOTHERAPY; MUCOCILIARY CLEARANCE; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT MUCOSA; REVIEW; SINGLE DRUG DOSE; ANIMAL; CLINICAL TRIAL (TOPIC); COMPLICATION; DRUG EFFECTS; ION TRANSPORT; PATHOPHYSIOLOGY;

ANIMALS; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; DIURETICS, OSMOTIC; DRUG SYNERGISM; HUMANS; ION TRANSPORT; MANNITOL; MUCOCILIARY CLEARANCE; RESPIRATORY MUCOSA; SALINE SOLUTION, HYPERTONIC;

EID: 77954656825     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.04.003     Document Type: Review

References (36)

1. Boucher R.C. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 2007, 261:5-16.
2. Tarran R., Button B., Picher M., Paradiso A.M., Ribeiro C.M., Lazarowski E.R., Zhang L., Collins P.L., Pickles R.J., Fredberg J.J., et al. Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections. J Biol Chem 2005, 280:35751-35759.
3. Wills P.J. Inhaled mannitol in cystic fibrosis. Expert Opin Investig Drugs 2007, 16:1121-1126.
4. Daviskas E., Robinson M., Anderson S.D., Bye P.T. Osmotic stimuli increase clearance of mucus in patients with mucociliary dysfunction. J Aerosol Med 2002, 15:331-341.
5. Eng P.A., Morton J., Douglass J.A., Riedler J., Wilson J., Robertson C.F. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996, 21:77-83.
6. Robinson M., Hemming A.L., Regnis J.A., Wong A.G., Bailey D.L., Bautovich G.J., King M., Bye P.T. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997, 52:900-903.
7. Robinson M., Regnis J.A., Bailey D.L., King M., Bautovich G.J., Bye P.T. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 1996, 153:1503-1509.
8. Donaldson S.H., Bennett W.D., Zeman K.L., Knowles M.R., Tarran R., Boucher R.C. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006, 354:241-250.
9. Levin M.H., Sullivan S., Nielson D., Yang B., Finkbeiner W.E., Verkman A.S. Hypertonic saline therapy in cystic fibrosis: evidence against the proposed mechanism involving aquaporins. J Biol Chem 2006, 281:25803-25812.
10. Elkins M.R., Robinson M., Rose B.R., Harbour C., Moriarty C.P., Marks G.B., Belousova E.G., Xuan W., Bye P.T. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006, 354:229-240.
11. Suri R., Metcalfe C., Lees B., Grieve R., Flather M., Normand C., Thompson S., Bush A., Wallis C. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001, 358:1316-1321.
12. Ratjen F. Restoring airway surface liquid in cystic fibrosis. N Engl J Med 2006, 354:291-293.
13. Clunes M.T., Boucher R.C. Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis. Curr Opin Pharmacol 2008, 8:292-299.
14. Wark P., McDonald V.M. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2009, CD001506.
15. Suri R., Marshall L.J., Wallis C., Metcalfe C., Bush A., Shute J.K. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. Am J Respir Crit Care Med 2002, 166:352-355.
16. Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis (ISIS Pilot) on World Wide Web URL: http://clinicaltrials.gov/ct2/show/study/NCT00546663.
17. Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS) on World Wide Web URL: http://clinicaltrials.gov/ct2/show/NCT00709280.
18. Jaques A., Daviskas E., Turton J.A., McKay K., Cooper P., Stirling R.G., Robertson C.F., Bye P.T., Lesouef P.N., Shadbolt B., et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008, 133:1388-1396.
19. Robinson M., Daviskas E., Eberl S., Baker J., Chan H.K., Anderson S.D., Bye P.T. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999, 14:678-685.
20. Minasian C., Wallis C., Metcalfe C., Bush A. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial. Thorax 2010, 65:51-56.
21. Bilton D., Robinson P., Cooper P., Charlton B. Randomized double blind, placebo-controlled phase III study of inhaled dry powder mannitol (Bronchitol) in CF. Pediatr Pulmonol 2009, S286.
22. Minasian C., Wallis C., Metcalfe C., Bush A. Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis. Pediatr Pulmonol 2008, 43:1078-1084.
23. Bartholdson S.J., Brown A.R., Mewburn B.R., Clarke D.J., Fry S.C., Campopiano D.J., Govan J.R. Plant host and sugar alcohol induced exopolysaccharide biosynthesis in the Burkholderia cepacia complex. Microbiology 2008, 154:2513-2521.
24. Deterding R.R., Lavange L.M., Engels J.M., Mathews D.W., Coquillette S.J., Brody A.S., Millard S.P., Ramsey B.W. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med 2007, 176:362-369.
25. Olivier K.N., Bennett W.D., Hohneker K.W., Zeman K.L., Edwards L.J., Boucher R.C., Knowles M.R. Acute safety and effects on mucociliary clearance of aerosolized uridine 5'-triphosphate +/- amiloride in normal human adults. Am J Respir Crit Care Med 1996, 154:217-223.
26. Bennett W.D., Olivier K.N., Zeman K.L., Hohneker K.W., Boucher R.C., Knowles M.R. Effect of uridine 5'-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am J Respir Crit Care Med 1996, 153:1796-1801.
27. Noone P.G., Bennett W.D., Regnis J.A., Zeman K.L., Carson J.L., King M., Boucher R.C., Knowles M.R. Effect of aerosolized uridine-5'-triphosphate on airway clearance with cough in patients with primary ciliary dyskinesia. Am J Respir Crit Care Med 1999, 160:144-149.
28. Thelin W.R., Boucher R.C. The epithelium as a target for therapy in cystic fibrosis. Curr Opin Pharmacol 2007, 7:290-295.
29. Deterding R., Retsch-Bogart G., Milgram L., Gibson R., Daines C., Zeitlin P.L., Milla C., Marshall B., Lavange L., Engels J., et al. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol 2005, 39:339-348.
30. Accurso FJ, Durham TA, Schaberg AE: Relationship between pulmonary exacerbations and lung function decline in a six month placebo-controlled trial of denufosol. In 32nd European Cystic Fibrosis Society Annual Conference. Brest, France; 2009.
31. Moss RB, Anbar RD, Wilmott RW, Barnes M, Schaberg AE, Durham TA, Accurso FJ: Phase 3 study of denufosol tetrasodium for the treatment of cystic fibrosis. In American Thoracic Society 2009 International Conference. San Diego, California; 2009.
32. Zhou Z., Treis D., Schubert S.C., Harm M., Schatterny J., Hirtz S., Duerr J., Boucher R.C., Mall M.A. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice. Am J Respir Crit Care Med 2008, 178:1245-1256.
33. Hirsh A.J., Zhang J., Zamurs A., Fleegle J., Thelin W.R., Caldwell R.A., Sabater J.R., Abraham W.M., Donowitz M., Cha B., et al. Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy) phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exp Ther 2008, 325:77-88.
34. Hirsh A.J., St George J., Thelin W., Stapleton K., Montgomery B., Boucher R., Johnson M.R. GS-9411: a potential aerosol pharmacotherapy for CF. Am J Respir Crit Care Med 2009, 179:A1195.
35. Coote K., Atherton-Watson H.C., Sugar R., Young A., MacKenzie-Beevor A., Gosling M., Bhalay G., Bloomfield G., Dunstan A., Bridges R.J., et al. Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. J Pharmacol Exp Ther 2009, 329:764-774.
36. Traynor-Kaplan A.E., Moody M., Nur M., Gabriel S., Majerus P.W., Drumm M.L., Langton-Webster B INO-4995 therapeutic efficacy is enhanced with repeat dosing in cystic fibrosis knockout mice and human epithelia. Am J Respir Cell Mol Biol 2010, 42:105-112.